The combination analgesic is primarily used for managing symptomatic relief when the intensity of symptoms related to physical discomfort is categorized as mild to moderate. Within its therapeutic area, it is indicated for addressing mild to moderate pain and is commonly applied in acute scenarios and conditions where other symptomatic support may be appropriate.

This medication assists with maintaining comfort when symptoms interfere with routine activities across various painful presentations, including headaches, toothache, period pain, and pain associated with musculoskeletal conditions. In its capacity for combined symptomatic management, the medication is applied across domains where additional symptomatic support is needed. It is relevant for managing both pain and general body aches accompanied by fever (pyrexia). This use helps address symptom clusters that may become intense or disruptive in contexts like cold and flu symptoms.

“This medication may assist with easing the overall symptom load during periods of heightened symptoms.”

Quick Fact: Applied for Acute Symptomatic Discomfort

Eligibility Map: Who Can and Cannot Use Codeine/Paracetamol — Official Regulatory Information

Populations for whom use is allowed: Adults and adolescents 12 to 18 years old for acute moderate pain not relieved by non-opioid analgesics alone.

Populations for whom use is not recommended: Adolescents (12–18) with compromised respiratory function (e.g., severe lung disease, obesity). Use for long-term treatment is not recommended.

Populations for whom use is contraindicated:

• Children younger than 12 years of age.
• Women who are breastfeeding.
• Patients known to be CYP2D6 ultra-rapid metabolizers.
• All paediatric patients (0–18) post-tonsillectomy/adenoidectomy for obstructive sleep apnoea.
• Patients with severe hepatic insufficiency or significant respiratory depression.

Age-related eligibility rules: Contraindicated below age 12. Older adults are permitted, but caution is required due to increased sensitivity and risk of organ impairment.

Condition-specific eligibility rules: Use requires caution in patients with severe renal or impaired hepatic function, raised intracranial pressure, or a history of substance abuse. The medicine is contraindicated during lactation.

---

Official Eligibility Statements:

• Use is contraindicated in children under 12 and in breastfeeding women.
• Use is contraindicated for all patients known to be ultra-rapid codeine metabolizers.
• Caution is required for patients with severe renal or any degree of hepatic impairment.

Connection to the overall eligibility profile: Official regulatory documents establish a strict eligibility profile defined by major safety constraints related to codeine's variable metabolism and respiratory effects, combined with the paracetamol component's risk of hepatotoxicity. These constraints lead to the absolute prohibition of the medicine in specific age, metabolic, and physiological groups.

Interactions with other medicines and products

Official regulatory information for Codeine + Paracetamol documents interaction patterns based on the pharmacological properties of both active components.

Contraindicated and Severe Combinations

The primary restriction is the contraindication against concurrent use with any other product containing Acetaminophen/Paracetamol to prevent exceeding the maximum dose. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated and requires a minimum separation period of 14 days. The combination is also contraindicated in children younger than 12 years of age.

Pharmacodynamic and CNS Effects

Concomitant use with Central Nervous System (CNS) depressants, including alcohol, sedatives, tranquilizers, and other opioid analgesics, is documented to result in additive CNS depression, increasing the risk of profound sedation and respiratory depression.

Metabolic Interactions

The Codeine component, a prodrug, is subject to CYP2D6-mediated pharmacokinetic interactions. Co-administration with CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine) may decrease the active metabolite Morphine concentration, officially resulting in reduced analgesic efficacy. Conversely, individuals documented as ultra-rapid metabolizers of CYP2D6 face a risk of increased opioid toxicity. The Paracetamol component requires close monitoring when used alongside oral anticoagulants such as Warfarin, due to the potential for altered effects.

Central Mu-Opioid Receptor Agonism (Codeine)

This mechanism is initiated as Codeine undergoes CYP2D6-mediated metabolism to its active form, Morphine. Morphine acts as an agonist on mu-opioid receptors (mu-ORs) located in the brain and spinal cord. mu-OR activation couples to Gi proteins, which inhibits adenylyl cyclase and opens inwardly-rectifying potassium channels. This leads to the hyperpolarization of neurons and restricts the release of excitatory pain neurotransmitters, fundamentally elevating the pain threshold and modulating the activity of the medullary cough center.

Selective Central Prostaglandin Modulation (Paracetamol)

Paracetamol primarily influences pathways associated with nociception and thermoregulation by acting as an inhibitor of the peroxidase site of the Cyclooxygenase (COX) enzyme, selectively in the Central Nervous System (CNS). This action reduces the synthesis of Prostaglandin E2 ( PGE2) in the hypothalamus. Decreased PGE2 levels result in the resetting of the body's thermoregulatory set-point and influence central nociceptive signal sensitivity.

Mechanistic Interaction via Dual Central Action

The co-modulation of both the opioid receptor system and the prostaglandin pathway engages two distinct mechanisms within the CNS. This leads to a supra-additive interaction on nociceptive signaling, which leverages multiple mechanistic pathways for central signal modulation.

The fixed-dose combination of Codeine and Paracetamol (Acetaminophen) is administered via the oral route in formulations such as tablets, capsules, and oral solutions. Use of the drug is guided by the principle of employing the lowest effective dosage for the shortest duration possible to manage acute symptoms.

Dosage and Frequency

The standard adult regimen involves taking a single dose on an as-needed (PRN) basis, with a required minimum interval of four to six hours between successive administrations. Limits are observed regarding the Paracetamol component: the maximum total daily intake from all sources must not exceed 4,000 mg (4 g). Moreover, the treatment course is designated for short-term use only, with continuous use typically restricted to no more than three consecutive days for acute indications. Oral suspensions, if used, must be shaken well prior to measurement.

Special Administration Rules

Use is restricted in children under 12 years and for adolescents (12–18 years) who have undergone specific surgeries. Dose adjustments are part of the protocol for vulnerable populations. Patients with severe hepatic or renal impairment necessitate a reduced initial dose or a prolonged dosing interval (e.g., up to 8 hours). Administration may occur independently of food, although taking the dose immediately after a full meal may result in a delayed onset of the analgesic effect.

Research Evidence / Overview of Studies for Кодеин + Парацетамол

---

Evidence for Use in Acute, Short-Term Pain

Research explored short-term symptom changes in populations studied with the combination of Codeine and Paracetamol. Research typically involves short-term Randomized Controlled Trials (RCTs), where study participants are randomly assigned to receive the combination, a placebo (an inactive substance), or another pain reliever. Research examined outcomes related to physical discomfort and how these were measured during a defined period. Findings describe patterns observed in the studies regarding measured changes in pain intensity when comparing the combination to a placebo. However, the evidence is limited and findings were mixed when trying to define a specific difference in reported results compared to Paracetamol administered alone. The follow-up durations were limited.

Evidence for Use in Post-Operative Pain Relief

Research has specifically explored the combination for conditions associated with acute or disruptive episodes immediately following surgery, such as minor dental procedures. These trials was evaluated in populations of adults and adolescents, focusing on outcomes reflecting daily functioning or activity level during the immediate recovery period. The data show patterns related to measured changes in pain scores in these specific post-operative settings. However, results apply only to the populations studied, and the evidence quality varies across studies, particularly when comparing different types of surgical procedures. This research provides insight into short-term changes but research does not determine whether an individual will respond similarly.

Long-Term Studies and Follow-Up Data

When researchers examined the long-term use of this combination, they found that the evidence is limited. Most of the core research consists of trials that focus on changes observed in defined time intervals, often lasting only a few hours to a few days. Therefore, the long-term effects are not fully established, and there is limited information for long-term outcomes regarding the use of the combination for conditions involving periods of heightened symptoms.

Common questions about Кодеин+Парацетамол (FAQ)

---

Q: Через какое время после приема начинает действовать Кодеин+Парацетамол?

The official regulatory information states that the pain-relieving effect typically reaches its maximum concentration approximately 2 hours after administration.

---

Q: Сколько по времени длится эффект от Кодеин+Парацетамол?

The duration of the pain-relieving effect generally persists between 4 and 6 hours. This timeframe is consistent with the minimum required interval between doses outlined in the official prescribing information.

---

Q: Может ли Кодеин+Парацетамол повлиять на управление автомобилем?

Official regulatory guidance indicates that the Codeine component can cause central nervous system effects such as drowsiness, dizziness, or poor coordination. These effects may impact the ability to drive or operate heavy machinery, which is noted in official safety warnings.

---

Q: Правда ли, что Кодеин+Парацетамол используют для лечения кашля?

Codeine is described in regulatory sources as a cough suppressant because it modulates the cough center in the brain. However, the official product labeling for this combination (Codeine/Paracetamol) lists its primary intended use as the management of pain and fever.

---

Q: Влияет ли прием Кодеин+Парацетамол на результаты анализов крови?

Official regulatory information indicates that laboratory monitoring may be used to check for unwanted effects on organs such as the kidneys or liver. Changes in laboratory values can detect severe adverse reactions, especially liver damage linked to the Paracetamol component.

---

Q: Почему Кодеин+Парацетамол отпускается по рецепту в некоторых странах?

This combination is classified as a prescription-only medication in many regions primarily due to the Codeine component. This regulatory restriction is linked to the classification of opioids and concerns documented in official sources regarding their potential for abuse, dependence, and addiction.

---

Q: Что делать, если пропустил прием Кодеин+Парацетамол?

Official consumer information outlines the approach to a missed dose. Labeling typically describes skipping the missed dose if it is almost time for the next scheduled dose, or taking it as soon as remembered, provided a specific minimum time interval is maintained before the subsequent administration.

---

Q: Что известно об использовании Кодеин+Парацетамол во время беременности?

Regulatory documents indicate that the use of this medication during pregnancy is generally considered when the potential benefit is judged to outweigh the documented risks to the developing fetus. Prolonged use carries the documented risk of causing neonatal opioid withdrawal syndrome in the newborn.

---

Q: Может ли развиться толерантность к обезболивающему эффекту Кодеин+Парацетамол?

According to official opioid warnings, tolerance may develop when opioid medicines like Codeine are used regularly over time. This effect is described as requiring higher amounts of the opioid component to potentially achieve the same level of pain relief that was initially experienced.

---

Q: Описаны ли взаимодействия Кодеин+Парацетамол с травяными добавками?

Official regulatory guidance notes that complementary or herbal remedies are generally not formally tested for their interactive effects with prescription medications. Therefore, information about the safe co-administration of this drug with many herbal supplements is often limited.

---

Q: Как узнать, нет ли у меня аллергии на компоненты Кодеин+Парацетамол?

Official product documents describe the signs of an allergic reaction or hypersensitivity, which may include rash, hives, swelling of the face or tongue, or difficulty breathing. The appearance of these symptoms is documented as requiring immediate clinical evaluation.

---

Q: Описывается ли синдром отмены при прекращении приема Кодеин+Парацетамол?

Official product information confirms that physical dependence and withdrawal syndrome may occur if the medicine is discontinued suddenly, especially following regular or extended use. Symptoms described in regulatory sources include restlessness, anxiety, muscle pain, nausea, or vomiting.

---

Q: Что делать, если при приеме Кодеин+Парацетамол появилась сыпь?

A skin rash is listed as a potential side effect in adverse reaction profiles. Official guidance indicates that urgent clinical evaluation is necessary if the rash is severe, involves blistering, or is accompanied by other signs of a severe allergic reaction, such as difficulty breathing.

---

Q: Влияет ли Кодеин+Парацетамол на артериальное давление?

Regulatory information indicates that opioids, including Codeine, are associated with the risk of compromising the body's ability to maintain stable blood pressure. This effect, which can result in hypotension (low blood pressure), may be related to mechanisms like peripheral vasodilation.

---

Q: Описано ли взаимодействие Кодеин+Парацетамол с кофеином?

Caffeine is a central nervous system stimulant, and it is sometimes included in combined pain formulations. However, specific details regarding the interaction between the simple Codeine and Paracetamol combination (without added caffeine) are not consistently described across all regulatory product labels.

---

Q: Почему может быть необходима специфическая консультация по приему Кодеин+Парацетамол при головной боли напряжения?

While this combination is used for pain management, regulatory constraints emphasize that treatment should be for short-term use only. Extended or frequent use of opioid-containing pain relievers is generally avoided when managing chronic conditions, such as recurring headaches.

---

Q: Каковы меры предосторожности при использовании Кодеин+Парацетамол для пожилых пациентов?

Official product labeling advises that caution is required when administering the drug to older adults. This is based on their potential increased sensitivity to the central and digestive effects of opioids and a higher risk of age-related impairment of organ function (liver or kidney). Regulatory protocols describe the need for potential dose adjustment in this population.

---

Q: Что такое 'потенциал злоупотребления' (Abuse Potential) применительно к Кодеин+Парацетамол?

Abuse potential is a regulatory term that refers to the likelihood of the drug being used intentionally for non-therapeutic purposes. This is linked to the Codeine component’s activity on the central nervous system, which may result in psychological or mood-altering effects, such as euphoria.

---

Q: Каков механизм действия Кодеин+Парацетамол, вызывающий запор?

The Codeine component, classified as an opioid, works by slowing the normal transit of material through the intestines. This slower movement increases water absorption from the stool, resulting in the hard, dry stools characteristic of opioid-induced constipation.

---

Q: Правда ли, что Парацетамол в составе Кодеин+Парацетамол может повредить почки?

Official reports indicate that the long-term, regular daily use of painkiller combinations containing Codeine and Paracetamol is associated with an increased risk of chronic kidney problems. Acute renal failure has also been reported in cases of severe poisoning or overdose of the medicine.

Storage and Disposal of Acetaminophen and Codeine Phosphate

The storage of Acetaminophen and Codeine Phosphate, a controlled substance, must follow strict regulatory guidelines to maintain product stability and prevent accidental ingestion or misuse.

---

Official Storage Requirements

The medication must be stored securely at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is mandatory to keep the container tightly closed and store the product out of the sight and reach of children and inaccessible to others. Storage conditions must protect the product from moisture and excessive heat.

---

Official Disposal Instructions

Unused or expired product should preferentially be disposed of through medicine take-back programs. If a take-back program is not readily available, the medication must be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash. The tablets must not be crushed before disposal. All personal information must be removed from the prescription label prior to discarding the empty packaging.